Checkpoint inhibitor (CPI)
Showing 1 - 25 of 8,510
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial in United
Terminated
- Carcinoma, Squamous Cell of Head and Neck
- +3 more
- ilixadencel
- Pembrolizumab
-
Coral Gables, Florida
- +4 more
Mar 1, 2022
Tumors Trial in Worldwide (Biopsy)
Completed
- Neoplasms
- Biopsy
-
San Francisco, California
- +10 more
Aug 10, 2022
Breast Cancer, Metastatic Breast Cancer, Breast Tumor Trial in Port Jefferson Station (SV-BR-1-GM, Cyclophosphamide, Interferon
Not yet recruiting
- Breast Cancer
- +4 more
- SV-BR-1-GM
- +4 more
-
Port Jefferson Station, New YorkNew York Cancers & Blood Specialists
Oct 2, 2023
Hepatocarcinoma, Lung Cancer, Melanoma Trial in Guanzhou (Checkpoint inhibitor (CPI) such as Pembrolizumab)
Recruiting
- Hepatocarcinoma
- +9 more
- Checkpoint inhibitor (CPI) such as Pembrolizumab
-
Guanzhou, Guangdong, ChinaThe Second Affiliated Hospital of Guangzhou Medical University
Feb 14, 2020
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Sacramento
Recruiting
- Advanced Colorectal Carcinoma
- +15 more
- Fermented Wheat Germ Extract
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Jul 26, 2023
Immune Checkpoint Inhibitor-related Cardiotoxicity
Not yet recruiting
- Immune Checkpoint Inhibitors, Cardiotoxicity
- Cardiac magnetic resonance
- (no location specified)
Nov 10, 2023
Severe Checkpoint Inhibitor Pneumonitis Trial in Beijing (Corticosteroids, Corticosteroids and Ruxolitinib)
Recruiting
- Severe Checkpoint Inhibitor Pneumonitis
- Corticosteroids
- Corticosteroids and Ruxolitinib
-
Beijing, Beijing, ChinaDepartment of Respiratory Medicine, Peking Union Medical College
Jun 12, 2023
Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,
Completed
- Gastrointestinal Tumor
- Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
- tislelizumab (BeiGene, China) combined with PD-1 inhibitor
-
Hangzhou, ChinaZhejiang Hospital
Sep 1, 2023
Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)
Not yet recruiting
- Inflammatory Arthritis
- Immune-related Adverse Event
- (no location specified)
Sep 13, 2023
Metastatic Solid Tumor, NSCLC, Gastric Cancer Trial (RO7496353, Atezolizumab, Capecitabine)
Not yet recruiting
- Metastatic Solid Tumor
- +3 more
- RO7496353
- +7 more
- (no location specified)
May 22, 2023
Determine Pro-Inflammatory Cytokine Kinetics During Immune
Not yet recruiting
- Non Small Cell Lung Cancer
- Melanoma
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Jan 30, 2023
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)
Enrolling by invitation
- Malignant Ascites
-
Taichung, Please Select, TaiwanChina Medical University Hospital
Feb 16, 2023
NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)
Not yet recruiting
- NSCLC Associated With Leptomeningeal Metastases
- Tislelizumab, pemetrexed
- (no location specified)
Nov 21, 2023
Immune Checkpoint Inhibitor Monotherapy or Combined With
Not yet recruiting
- Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
- Immune checkpoint inhibitor
-
Guangzhou, Guangdong, ChinaDepartment of Minimally Invasive and Interventional Radiology, L
Jan 30, 2023
Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with
Recruiting
- Lung Squamous Cell Carcinoma
- To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
-
Yancheng, Jiangsu, ChinaYancheng Clinical College of Xuzhou Medical University
Mar 21, 2023
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)
Not yet recruiting
- Nasopharyngeal Carcinoma
- +3 more
- Intensity Modulated Radiation Therapy
- +3 more
- (no location specified)
Jul 11, 2023
Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)
Recruiting
- Advanced Biliary Tract Cancer
- Sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 22, 2023
Stage IV NSCLC Trial in Houston (Poly ICLC, IVIG)
Not yet recruiting
- Stage IV NSCLC
- Poly ICLC
- IVIG
-
Houston, TexasMichael E. DeBakey VA Medical Center, Houston, TX
Sep 28, 2023
Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- (no location specified)
Aug 1, 2023
EXploring Immune-related Adverse Events of Immune checkpoinT
Active, not recruiting
- Cancer
- +2 more
- Immune checkpoint inhibitor
-
Paris, France
- +1 more
Jul 5, 2023
Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in
Active, not recruiting
- Melanoma
- Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
- Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
-
Toulouse, FranceInstitut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022
Development ofEORTC Immune Checkpoint Inhibitor-specific Quality
Recruiting
- Cancer
- +2 more
-
Paris, FranceInstitut Curie
Nov 2, 2022